Clinical Trial Update: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing Onvansertib plus FOLFIRI and Bevacizumab versus FOLFIRI and Bevacizumab for second-line metastatic colorectal cancer with KRAS …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI regimen (irinotecan + leucovorin + 5-fluorouracil)
• Onvansertib (onvansertib)

Snippet

Sponsor: Cardiff Oncology | Conditions: Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED